Neuromuscular

Theresa Sevilis, DO, writes on picking a career path in medicine as a woman, and how deciding to jump ship from a traditional path was among the best decisions she's made.

The assistant clinical professor at Vanderbilt University School of Medicine shared what National Women Physicians Day means to her, and the history behind its celebration. [WATCH TIME: 6 minutes]

For women, the decision to opt for an unconventional career path can be inspired by conflicting responsibilities and balancing life with work. But, as Sana Syed, MD, MPH, explains, following your passion is still an achievable dream despite these challenges.

Treatment with blarcamesine resulted in statistically significant improvements on the new primary end point and significantly reduced Rett syndrome symptoms through changes in potential biomarkers of disease pathology.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

Expert clinicians offer their insight on conducting trials in pediatric migraine, the pipeline of Alzheimer therapies, disorders of consciousness and COVID-19, and more.

Here's what is coming soon to NeurologyLive®.

Neurology News Network for the week ending January 29, 2022.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 28, 2022.

Take a look at 5 of the most-anticipated clinical trial data readouts expected in 2022 that neurology health care professionals should keep their eyes on.

The submission to the FDA is supported by interim data from the RAINBOWFISH trial (NCT03779334), as all 5 babies treated with risdiplam maintained the ability to swallow and feed exclusively orally after 12 months.

The FDA accepted the new drug application for priority review, setting a PDUFA action date of May 12, 2022.

Patients on the study drug demonstrated improvements in several different exploratory cardiac end points, including NT-proBNP and echocardiographic parameters relative to placebo.

Here's what is coming soon to NeurologyLive®.

Neurology News Network for the week ending January 22, 2022. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 21, 2022.

Zhittya Genesis Medicine announced the trial to evaluate its biological drug, FGF-1, which is administered via an intranasal delivery device, in a cohort of individuals with mild to moderate ALS.

Those who had crossovers of ALS and frontotemporal dementia had structural and functional resemblance to the patterns of damage of those with only behavioral variant frontotemporal dementia.

Here's what is coming soon to NeurologyLive®.

Expert clinicians offer their insight on costs of Alzheimer drug development, a new agent for generalized myasthenia gravis, migraine in the emergency department, educational sleep medicine “boot camps”, AES 2021, and more.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 14, 2022.

Despite not providing additional, clinically relevant benefit for patients with amyotrophic lateral sclerosis as an add-on to standard therapy, the intravenous treatment was feasible and well tolerated.

Only 30% of the observed cohort of more than 150 children had their hypertonia type specified as spasticity and/or dystonia by age 5 years, highlighting a need for additional education efforts.

Catch up on any of the neurology news headlines you may have missed over the course of the last month, compiled all into one place by the NeurologyLive® team.

Here's what is coming soon to NeurologyLive®.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 7, 2022.

Here's what is coming soon to NeurologyLive®.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 31, 2021.

Take a look back at some of the most-viewed, top video series with key experts in neurology and their in-depth discussions, part of NeurologyLive®'s Year in Review.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jennifer Majersik, MD, MS.